American Diabetes Association
Figures_and_tables_in_supplementary_material_3.pdf (346.03 kB)

Serum Galectin-3 and Subsequent Risk of Coronary Heart Disease in Subjects With Childhood-Onset Type 1 Diabetes: A Cohort Study

Download (346.03 kB)
posted on 2021-01-06, 22:31 authored by Maryam Saeed, German Tapia, Inger Ariansen, Lars C. Stene, Ingebjørg Seljeflot, Grethe S. Tell, Torild Skrivarhaug, Geir Joner
Objective: To study whether serum galectin-3 and other biomarkers of inflammation predict coronary heart disease (CHD) in subjects with longstanding childhood-onset type 1 diabetes.

Research, design and methods: A population-based nation-wide cohort of 299 subjects with type 1 diabetes diagnosed in Norway at age <15 years during 1973-1982. They were examined in 2002-2003 at mean age of 33 years (range 21-44), with mean diabetes duration of 24 years (range 19-30). Subjects were followed through December 31, 2017 for their first CHD event registered by a hospitalization or cause of death using nation-wide registries. Stored serum samples were available for 296 subjects and analyzed for interleukin (IL)-6, IL-6 receptor, IL-18, high sensitivity-C-reactive protein, matrix metalloproteinases-9, tissue inhibitor of metalloproteinase-1, galectin-3 and high sensitivity troponin T (hs-TNT). Adjusted hazard ratios (aHR) for CHD per standard deviation increase in biomarker were estimated using Cox regression.

Results: Of 295 subjects, 40 (13.6%) had documented CHD event during mean follow-up of 14.4 years (range 0.5 - 16). IL-6 (aHR 1.32, 95% CI: 1.07 – 1.63), galectin-3 (aHR 1.44, 95% CI: 1.09 – 1.80) and TIMP-1 (aHR 1.37, 95% CI 1.04 – 1.81) were significant predictors of CHD after adjustment for conventional risk factors.

Conclusion: Galectin-3 was significantly associated with future CHD in subjects with type 1 diabetes, and if the results are replicated in larger studies it may aid in prediction together with conventional risk factors for CHD.


This project has been made possible by fundings from the Dam Foundation, University of Oslo and Oslo University Hospital.